7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

Please reload

Featured Posts

Potentia Receives a Phase II STTR Grant

September 1, 2008

Louisville, Ky. – Potentia Pharmaceuticals, together with academic collaborators, received a Phase II STTR grant from the National Eye Institute to push forward their development of a new, less invasive delivery technology for ocular therapeutics. This grant, involving a collaboration with the Lions Eye Center of the University of Louisville, revolves around the use of disease-targeted drug-eluting polymeric nanoparticles that are administered intravenously.



Please reload